A series of novel metal [Cu(II), Co(II), Ni(II) and Zn(II)] complexes have been prepared with an azo ligand, 4-imino-3-[(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)diazenyl]-4Hpyrimido[2,1b][1,3]benzothiazol-2-ol [HL] derived from benzothiazole nucleus. The newly synthesized complexes were characterized by investigating various spectroscopic and analytical techniques such as UV–Vis, FT-IR, ¹H NMR, Mass, Powder-XRD, TGA, ESR, SEM, EDAX and VSM (Vibrating Sample Magnetometer). The azo ligand and its metal complexes have been investigated for their anti-tuberculosis, anticancer and DNA binding studies. The tested compounds showed moderate to good antituberculosis activity compared with the standards. In addition, all the prepared compounds exhibited a significant hypochromicity and considerable groove-binding property to the CT-DNA. The anticancer activity of the Zn(II) complex exhibited IC₅₀ value less than 50 compared to other compounds against A549 and K562 cell lines.

用偶氮配体4-亚氨基-3-[（4,5,6,7）制备了一系列新型金属[Cu（II），Co（II），Ni（II）和Zn（II）]配合物-衍生自苯并噻唑核的-四氢-1,3-苯并噻唑-2-基）二氮烯基] -4Hpyrimido [2,1b] [1,3]苯并噻唑-2-醇[ HL ]。通过研究各种光谱学和分析技术（例如UV-Vis，FT-IR，^1）对新合成的复合物进行了表征。1 H NMR，质量，粉末XRD，TGA，ESR，SEM，EDAX和VSM（振动样品磁强计）。已对偶氮配体及其金属配合物进行了抗结核，抗癌和DNA结合研究。与标准品相比，所测试的化合物显示出中等至良好的抗结核活性。另外，所有制备的化合物均表现出显着的低色性和对CT-DNA的显着的凹槽结合性质。与其他化合物相比，Zn（II）配合物对A549和K562细胞系的抗癌活性IC ₅₀值小于50。